Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|August 11, 2022

Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

Author(s)Stephen J. Freedland, MD

Dr Freedland discusses the clinical implications of using genomic test results for management of patients with prostate cancer.

Episodes in this series

EP. 1 Staging, Grading, and Risk Stratification of Prostate Cancer

EP. 1 Staging, Grading, and Risk Stratification of Prostate Cancer

EP. 2 Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP. 2 Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP. 3 Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP. 3 Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP. 4 The Potential for Overtreatment or Undertreatment of Prostate Cancer

EP. 4 The Potential for Overtreatment or Undertreatment of Prostate Cancer

Stephen J. Freedland

EP. 5 Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

Stephen J. Freedland

EP. 6 Available Genomic Tests for Clinically Localized Prostate Cancer

Stephen J. Freedland

EP. 7 Clinical Study Data in Prostate Cancer Genomic Testing

Stephen J. Freedland

EP. 8 Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

Stephen J. Freedland

EP. 9 Exciting Emerging Data in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

ByHannah Clarke

December 12th 2025

2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness

ByMichael S. Cookson, MD, MMHC, FACS

December 10th 2025

FDA gives nod to trial of alpha-radiation therapy for prostate cancer

ByHannah Clarke

December 9th 2025

Trial launches of PSMA-targeting radioligand therapy in mCRPC

ByHannah Clarke

December 8th 2025

Alexandra Sokolova, MD, outlines TRIPLE-SWITCH trial in mCSPC

ByAlexandra Sokolova, MD

December 8th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.